LPL Financial LLC Has $561,000 Stock Position in Grifols, S.A. (NASDAQ:GRFS)

LPL Financial LLC increased its position in shares of Grifols, S.A. (NASDAQ:GRFS) by 25.0% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 75,398 shares of the biotechnology company’s stock after acquiring an additional 15,067 shares during the quarter. LPL Financial LLC’s holdings in Grifols were worth $561,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. R Squared Ltd purchased a new position in Grifols during the 4th quarter worth approximately $28,000. GAMMA Investing LLC boosted its position in shares of Grifols by 44.5% in the fourth quarter. GAMMA Investing LLC now owns 4,959 shares of the biotechnology company’s stock worth $37,000 after buying an additional 1,527 shares during the period. Blue Trust Inc. grew its holdings in shares of Grifols by 254.0% during the fourth quarter. Blue Trust Inc. now owns 6,927 shares of the biotechnology company’s stock valued at $52,000 after buying an additional 4,970 shares in the last quarter. Envestnet Portfolio Solutions Inc. acquired a new position in Grifols during the fourth quarter valued at $77,000. Finally, Raymond James Financial Inc. purchased a new stake in Grifols in the 4th quarter worth about $91,000.

Grifols Stock Down 0.1 %

Grifols stock opened at $7.18 on Friday. The firm’s 50 day moving average price is $7.48 and its two-hundred day moving average price is $7.77. The firm has a market cap of $4.94 billion, a PE ratio of 6.14 and a beta of 0.41. Grifols, S.A. has a twelve month low of $5.79 and a twelve month high of $9.96. The company has a debt-to-equity ratio of 1.11, a quick ratio of 0.79 and a current ratio of 2.26.

Wall Street Analysts Forecast Growth

Separately, Morgan Stanley began coverage on Grifols in a research note on Wednesday, February 12th. They set an “overweight” rating on the stock.

Grifols Company Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.